NANORETE, INC. — Department of Defense SBIR Phase II: nanoRETE is a developing a nanoparticle-based biosensor technology platform that has the a

Description

nanoRETE is a developing a nanoparticle-based biosensor technology platform that has the ability for real-time detection of pathogens. Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (Mtb) that primarily affects the lungs. In Phase I research, nanoRETE demonstrated proof-of-concept of an electrochemical nano-bead biosensor for measuring plasma cytokine and chemokine concentrations that have been identified as biomarkers of Mtb infection. In Phase II research, an optimized electrochemical multiplex assay for rapid TB detection will be developed using a prototype biosensor cartridge. The prototype will then be tested with clinical samples. Finally, a fully-integrated"sample in-results out"TB screening device will be designed and experimental plans for Phase III laid out.